Nice try but if you read the whole article you would see that the problem primarily lies in the quality of the manufactured drugs not necessarily the clinical trials. I would suggest peer reviewed nature of a2 trials will standup
2 new studies from A2MC, page-28
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.58 |
Change
-0.060(1.06%) |
Mkt cap ! $4.058B | |||
| Open | High | Low | Value | Volume |
| $5.62 | $5.63 | $5.57 | $1.062M | 189.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 6993 | $5.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.59 | 1814 | 9 |
View Market Depth
| Last trade - 11.52am 12/09/2024 (20 minute delay) ? |
| A2M (ASX) Chart |